Compare ADMA Biologics Inc (ADMA) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Oatly Group AB - ADR — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Oatly Group AB - ADR trades at $9.38 (market cap $301.32M). The key difference: ADMA Biologics Inc is far larger — about 7.1× Oatly Group AB - ADR's market cap. Which is the better fit depends on your goals.
| ADMA | OTLY | |
|---|---|---|
Market Cap | $2.13B | $301.32M |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $18.54 |
52-Week Low | $7.60 | $8.03 |
Enterprise Value | $2.20B | $798.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OTLY trades at $9.65, down 3.02% today, with a bullish technical signal from moving averages and ADX indicators. Revenue grew to $862.46M in 2025, but the company reported a net loss of $152.77M, with negative cash flow and high debt levels. Recent news includes a partnership with Nespresso and upcoming Q2 2026 earnings on July 22, 2026.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and a strong brand offer potential. Key risks include high leverage and competitive pressures. Analysts are divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
